Transcatheter heart-valve replacement, or TAVR, is a nonsurgical means of replacing a faulty transcatheter valve in the heart. TAVR sales ramped more than 12% — or almost 11% in constant currency — to $1.15 billion. That easily beat expectations for $1.1 billion, according to FactSet. The strong sales follow a study unveiled this week that showed superior clinical outcomes after a year for patients who underwent TAVR rather than surgery to replace their valves. These were patients who were considered to hav ...